Exenatide

Exendin-4 was isolated from the venom of Heloderma suspectum and shares about 53% homology with human GLP-1, including a glycine at position 2 that makes it inherently resistant to DPP-4. It is a full GLP-1 receptor agonist: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying and central satiety. The immediate-release form (Byetta) has a 2-3 hour half-life and is dosed before meals to blunt postprandial excursions; the extended-release form (Bydureon) encapsulates the same peptide in biodegradable PLGA microspheres for weekly dosing. Because it is a non-human peptide, anti-drug antibodies are considerably more common than with human-sequence analogues.

Targets: GLP-1 receptor

• · 5 mcg twice daily for one month, then 10 mcg twice daily if tolerated. Note the microgram scale here - these are tiny doses compared with modern analogues.
• · Fixed 2 mg weekly, no titration. The microsphere suspension must be mixed vigorously before injecting and needs a wider-bore needle.

Work out your exact syringe units →

• very commonNausea— Affected around 40% of patients on immediate-release exenatide.
• very commonInjection-site nodules— Characteristic of the extended-release microspheres; can persist for weeks.
• commonAnti-drug antibodies— High-titre antibodies can reduce efficacy - a consequence of the non-human sequence.
• rareAcute kidney injury— Reported mostly in the setting of dehydration from vomiting.
• rarePancreatitis

• eGFR below 30 mL/min/1.73 m2 - exenatide is renally cleared, unlike most other GLP-1 agonists.
• Personal or family history of medullary thyroid carcinoma or MEN2 (extended-release form carries the boxed warning).
• History of pancreatitis.
• Severe gastroparesis.

• cautioninsulin-analogues — Hypoglycaemia risk, particularly with prandial insulin given the shared mealtime timing.
• cautionsulfonylureas (glimepiride, gliclazide, glipizide) — Real hypoglycaemia risk - unlike exenatide alone, sulfonylureas drive insulin release independently of glucose. Labels advise reducing the sulfonylurea dose when a GLP-1 agonist is started.
• redundantsemaglutide — Same receptor.

• · HbA1c and postprandial glucose.
• · Renal function - this is the one GLP-1 where creatinine genuinely matters.
• · Weight.

FDA- and EMA-approved but commercially discontinued in the US; research-grade exendin-4 is widely sold.

• Holman et al. 2017, EXSCEL cardiovascular outcomes trial, NEJM (trial)
• Eng et al. 1992, isolation of exendin-4 from Heloderma suspectum venom, J Biol Chem (preclinical)
• Byetta and Bydureon BCise US prescribing information (label)

Exendin-4 is the reference molecule for the entire field and it is worth understanding why. It shares only about 53% sequence identity with human GLP-1 but is a more potent GLP-1 receptor agonist, because the C-terminal nine-residue extension folds into a Trp-cage motif that stabilises binding to the receptor's extracellular domain. Two structural facts made it a drug where native GLP-1 could never be one: glycine rather than alanine at position 2 blocks DPP-4 cleavage entirely, and the Trp-cage raises affinity. Everything since - liraglutide's palmitate, semaglutide's di-acid, lixisenatide's lysine tail, efpeglenatide's Fc conjugate - is an attempt to give a human-sequence or exendin-based peptide the durability that exendin-4 has naturally, and then extend it further. Clinically the short half-life produces a distinctive profile. Because plasma levels fall to nothing between doses, the gastric-emptying effect does not tachyphylax the way it does with continuous long-acting exposure, so twice-daily exenatide is disproportionately good at flattening postprandial glucose and disproportionately weak at reducing fasting glucose and weight. The extended-release microsphere version inverts this: continuous exposure gives better HbA1c and fasting glucose, loses much of the prandial advantage, and reaches steady state only after six to eight weeks - which also means it keeps releasing for about ten weeks after the last injection, so stopping is not immediate. The other consequence of a non-human sequence is immunogenicity: anti-drug antibodies are far more common than with human-sequence analogues, and high-titre antibodies measurably reduce efficacy. EXSCEL was neutral on cardiovascular outcomes, which alongside positive LEADER, SUSTAIN-6, REWIND, HARMONY and AMPLITUDE-O suggests cardioprotection is not a uniform class effect.

Two things. The first is the microgram scale: 5 and 10 mcg are doses that cannot be measured accurately from a reconstituted research vial without a very dilute preparation, and people used to milligram-scale peptides get this wrong by an order of magnitude. The second is renal. Exenatide is the only member of this class where the kidney clears the drug, so vomiting-induced dehydration creates a feedback loop - less clearance, higher levels, more vomiting - and the acute kidney injury reports in the label came from exactly that. Also worth knowing: the extended-release microspheres leave persistent subcutaneous nodules that can last weeks, and because release continues for around ten weeks, stopping the drug does not stop the drug.

1. 5 mcgMonth 1 — Immediate-release, twice daily within 60 minutes before the morning and evening meals. Note the microgram scale - this is a thousandth of a semaglutide dose.
2. 10 mcgMonth 2 onward — Maximum immediate-release dose. Never dose after a meal; the entire mechanism depends on the drug being present before food arrives.
3. 2 mgAlternative regimen, from week 1 — Extended-release microspheres, fixed 2 mg once weekly with no titration. Takes 6-8 weeks to reach steady state and keeps releasing for about 10 weeks after the last dose.

• GLP-1 receptor (GLP1R) — High-affinity full agonist, generally reported as more potent than native GLP-1 at the human receptor, driven by the C-terminal Trp-cage extension

  Glucose-dependent insulin secretion, glucagon suppression, and a profound and non-tachyphylactic delay in gastric emptying that dominates the clinical picture for the immediate-release form.

• EXSCEL Phase 3 cardiovascular outcomes · n=14752 · 165 weeks · 2017

  Neutral on major adverse cardiovascular events - non-inferior to placebo but not superior, which is why cardioprotection is not considered a uniform class effect.

Immediate-release: acts on the meal it precedes, within the hour. Steady state within a day. Extended-release: an initial release burst in the first days, a trough, then a slow climb to steady state over 6-8 weeks, and persistent release for roughly 10 weeks after the last injection.

Historically exenatide was the GLP-1 you added to a sulfonylurea and metformin, and that is also where its hypoglycaemia risk came from. Its practical relevance now is as research-grade exendin-4, where the honest assessment is that it is a worse version of drugs that are easier to obtain. Where it is genuinely non-redundant is alongside a long-acting agent for someone whose problem is specifically postprandial excursions - a long-acting GLP-1 tachyphylaxes on gastric emptying and exendin-4 does not - but that is a combination with no trial support and a real hypoglycaemia risk. Do not combine with lixisenatide; they are the same molecule with a different tail.

Against lixisenatide: nearly the same molecule, and lixisenatide's hexa-lysine tail makes it slightly higher affinity and shorter acting. Against liraglutide and semaglutide: exenatide loses on weight, on HbA1c, on injection frequency and on immunogenicity, and wins only on postprandial glucose. Against the whole modern class: this is the scaffold everything else was built on, and its main value now is understanding why the modern drugs are shaped the way they are. EXSCEL being neutral while LEADER, SUSTAIN-6, REWIND, HARMONY and AMPLITUDE-O were positive is the single most useful comparative fact about it.

Both Byetta and the Bydureon line have been commercially discontinued in the US, so there is no meaningful current retail price. Research-grade exendin-4 is sold cheaply as a laboratory reagent, but the microgram dosing makes it impractical.

• ?The Byetta label does not state absolute subcutaneous bioavailability or plasma protein binding, so both are left null.
• ?Receptor affinity relative to native GLP-1 is described qualitatively in the literature; a specific verified Ki was not resolved in this session.
• ?The reported incidence of anti-drug antibodies varies substantially between studies and assay methods.
• ?Whether EXSCEL's neutrality reflects the molecule, the trial's high dropout rate or its open-label background therapy has never been settled.

• Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes Holman RR et al., N Engl J Med, 2017 · PMID 28910237

  EXSCEL. The neutral cardiovascular outcomes trial that complicates any claim of a uniform GLP-1 class effect.

• Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom Eng J, Kleinman WA, Singh L, Singh G, Raufman JP, J Biol Chem, 1992 · PMID 1313797

  The origin paper. J Biol Chem 1992;267:7402-5. Every drug in this class descends from this molecule.

• Exendin-4, a new peptide from Heloderma suspectum venom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini Malhotra R et al., Regul Pept, 1992 · PMID 1279756

  Companion 1992 paper characterising the peptide's pancreatic activity.

• BYETTA (exenatide) injection - US prescribing information, sections 11 and 12.3 AstraZeneca Pharmaceuticals LP, DailyMed

  Source for the verified 39-residue amino acid sequence, molecular formula, 2.1-hour tmax, 28.3 L volume of distribution, 9.1 L/h clearance and glomerular filtration as the elimination route.